Real Price to Acquire Entire Company: 23andMe Inc (ME)

Brandmark of 23andMe Holding Co. (ME)

23andMe Holding Co. (ME) possesses a unique array of genetic data and patents protected by strict FDA oversight. The business relies on automated DNA processing lines that replace manual labor. This price chart demonstrates an Enterprise Value of . The company is currently implementing cloud-based AI systems for high-precision analysis of customer profiles and the automated identification of medical risks.

23andMe Inc (ME) Enterprise Value: for the period 07/04/2022 - 10/30/2026

Summary analytical data breakdowns for 23andMe Holding Co. (ME)

- market value and analyst target forecast:
Market Price 23andMe Holding Co|ME - Price Target Chart
- company stock exchange capitalization indicators:
Market Valuation 23andMe|ME - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share 23andMe|ME - Book Capitalization|Capitalization to Book Value Ratio 23andme.com|ME - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital 23andMe Holding Co.|ME - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio 23andme.com|ME - Company Aggregate Debts|Debts to Book Capitalization 23andMe|ME - Company Long-Term Debt|Company Short-Term Debt 23andMe|Immediate Liquidity 23andme.com
- earnings and market multiples details:
ME - Company Net Income
Summary company analytics:ME (23andMe Holding Co)
Original product of 23andMe Holding Co

23andMe Holding Co. (ME) expenditures on cybersecurity and digital sovereignty compliance directly impact its capital structure, as reflected in the calculated enterprise value. This indicator aggregates market capitalization and net debt to determine the total cost of acquiring the business, and its dynamics allow investors to assess the real price of assets while accounting for debt load and liquidity.

Competitors of 23andMe Holding Co. (ME)

Agilent Technologies, Inc. (A) - Total Enterprise Value|DGX - Total Company Value|Illumina Platform (ILMN) - Real Price to Acquire Entire Company|EXAS: Enterprise Value|Total Enterprise Value revvity.com (RVTY)|BIO (Bio-Rad) - Enterprise Value|Business Value NNNN (Anbio Biotechnology Ltd)|Enterprise Value SHC|Enterprise Value QuidelOrtho Inc. (QDEL)|Total Company Value OPKO Health, Inc. OPK|CDNA: Business Value|Maravai LifeSciences Holdings, Inc. - Enterprise Value|FLGT - Enterprise Value|Fluidigm (LAB) - Total Company Value|CTKB (Cytek Corp) - Total Company Value|Real Price to Acquire Entire Company OSUR|Total Enterprise Value Exagen Diagnostics XGN|Total Company Value MDxHealth (MDXH)|Company Buyout Price Lucid Diagnostics, Inc.|Enterprise Value PRE (Prenetics)|Company Buyout Price Insight Molecular Diagnostics, Inc. (IMDX)|TRIB - Total Company Value|Company Buyout Price prophaselabs.com PRPH|Ainos (AIMD) - Total Company Value|Real Price to Acquire Entire Company Co-Diagnostics Inc|HSCS (Heart Test Laboratories Inc.) - Enterprise Value|Enterprise Value Biomerica Inc|Total Company Value Cardio Diagnostics (CDIO)|viraxbiolabs.com - Business Value|Enterprise Value BJDX (Bluejay Diagnostics, Inc.)|AWH: Business Value|AXDX - Total Company Value|Centogene N.V. (CNTG) - Real Price to Acquire Entire Company|ENZ: Enterprise Value|Total Enterprise Value Fresh2 Group (FRES)|Real Price to Acquire Entire Company GENE|PMD: Value Adjusted for Debt and Cash